IB
MDGL icon

Intrust Bank’s Madrigal Pharmaceuticals MDGL Stock Holding History

Intrust Bank’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$452K Buy
863
+15
+2% +$7.17K 0.04% 277
2025
Q4 		$494K Buy
848
+174
+26% +$88.9K 0.04% 257
2025
Q3 		$309K Buy
+674
New +$251K 0.03% 332

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Intrust Bank's MDGL Position: Q1 2026 in Review

Intrust Bank increased its Madrigal Pharmaceuticals (MDGL) stake by 1.8% in Q1 2026, buying an estimated $7.17K and bringing the position to 863 shares worth $452K. The position accounts for 0.04% of the portfolio, ranked #277.

Intrust Bank first reported a position in MDGL in Q3 2025 and has held it in 3 quarters since. The position peaked at $494K in Q4 2025. 378 funds tracked by Wall St. Rank hold MDGL as of Q1 2026.

  • Intrust Bank held 863 shares of Madrigal Pharmaceuticals worth $452K as of Q1 2026.
  • Intrust Bank bought 15 Madrigal Pharmaceuticals shares in Q1 2026, an estimated $7.17K.
  • Madrigal Pharmaceuticals made up 0.04% of Intrust Bank's portfolio in Q1 2026, its #277 holding.
  • Intrust Bank first reported a position in Madrigal Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • Intrust Bank's Madrigal Pharmaceuticals position peaked at $494K in Q4 2025.
  • 378 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2026.

Based on Intrust Bank's 13F filing for Q1 2026, filed 6 May 2026.